• No results found

Epidemiological Studies of Multiple Sclerosis in Sweden with Focus on the County of Värmland

N/A
N/A
Protected

Academic year: 2021

Share "Epidemiological Studies of Multiple Sclerosis in Sweden with Focus on the County of Värmland"

Copied!
1
0
0

Loading.... (view fulltext now)

Full text

(1)

Epidemiological Studies of

Multiple Sclerosis in Sweden with

Focus on the County of Värmland

Inger Boström

Linköping University medical dissertations, No. 1286

Linköping University medical dissertations, No. 1286 IKE/Neurologi Linköpings universitet 581 83 Linköping www.liu.se Ep ide m iolog ica l S tud ie s of M ulti pl e S cle rosi s i n S we de n wi th F ocu s o n t he C ou nty of V ärm la nd Inge r B os trö m 20 12

References

Related documents

social/lifestyle activities were found in the sub-groups of people with MS with normal attention; normal manual dexterity; ability to walk without walking aid and support from

The third used immunomodula- tory or immunosuppressive intervention (natalizumab, mitoxantrone or rituximab) and assessed MS patients pre- and 12-24 months post-treatment.

The third used immunomodulatory or immunosuppressive intervention (natalizumab, mitoxantrone or rituximab) and assessed MS patients pre- and 12-24 months post-treatment.

This process in- cludes innate immune system (macrophages, microglia, natural killer cells) and adaptive immune system (B- and T lymphocytes). Thus, both humoral..

Some of the definitions include the term “same basic product,” or variations on that theme: multimarketing occurs “when a company uses separate channels to sell the same product

Epidemiological Studies of Multiple Sclerosis in Sweden with Focus on the County of Värmland. Inger Boström February

Aims: The aims of this thesis were to evaluate rituximab as a treatment alternative in relapsing remitting MS (RRMS) by describing the clinical effect and patient

Aims: The aims of this thesis were to evaluate rituximab as a treatment alternative in relapsing remitting MS (RRMS) by describing the clinical effect and patient related